Aria O’Brien, a fifth-grader at Haine Middle School in the Seneca Valley School District, was one of five winners in a ...

The biotech already sells one drug for HER2-positive breast cancer – oral HER2 inhibitor Nerlynx (neratinib) – and its main R&D focus is on extending its use into multiple breast cancer settings.